Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Non-Current Deferred Tax Liability (2022 - 2023)

Zentalis Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 2 years, most recently at $756000.0 for Q1 2023.

  • Quarterly results put Non-Current Deferred Tax Liability at $756000.0 for Q1 2023, down 51.16% from a year ago — trailing twelve months through Mar 2023 was $756000.0 (down 51.16% YoY), and the annual figure for FY2022 was $15.0 million, changed.
  • Non-Current Deferred Tax Liability for Q1 2023 was $756000.0 at Zentalis Pharmaceuticals, down from $15.0 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for ZNTL hit a ceiling of $15.0 million in Q4 2022 and a floor of $756000.0 in Q1 2023.